股本结构
单位：万股
| 公告日期 | 2026-08-12 | 2026-07-14 | 2026-08-12 | 2026-05-13 | 2026-05-13 | 2026-04-10 |
|---|---|---|---|---|---|---|
| 证券总股本 | 3924.21 | 3887.04 | 3509.40 | 3509.39 | 3505.27 | 3484.55 |
| 普通股本 | 3924.21 | 3887.04 | 3509.40 | 3509.39 | 3505.27 | 3484.55 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-07 | 2026-07-14 | 2026-06-30 | 2026-05-08 | 2026-03-31 | 2026-03-17 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-12 | 3924.21 | 未披露 | 定期报告 | 2026-08-07 |
| 2026-07-14 | 3887.04 | 未披露 |
更多>>
Common stock offered 3,776,436 shares by the company
|
2026-07-14 |
| 2026-08-12 | 3509.40 | 未披露 |
更多>>
From March 31,2026 to June 30,2026
Exercise of common stock options
|
2026-06-30 |
| 2026-05-13 | 3509.39 | 未披露 | 定期报告 | 2026-05-08 |
| 2026-05-13 | 3505.27 | 未披露 |
更多>>
From December 31,2025 to March 31,2026
Exercise of common stock options
Issuance of common stock for conversion of the K2 term loan, net of issuance
Restricted stock units vesting
Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs
|
2026-03-31 |
| 2026-04-10 | 3484.55 | 未披露 | 定期报告 | 2026-03-17 |
| 2026-03-16 | 3194.55 | 未披露 | 定期报告 | 2026-03-09 |
| 2026-03-16 | 3192.35 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Exercise of common stock options
Issuance of common stock and pre-funded warrants in private placement, net of issuance costs
Issuance of common stock for conversion of the K2 term loan, net of issuance costs
Restricted stock units vesting
|
2025-12-31 |
| 2025-11-12 | 3106.63 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-11-28 | 3106.63 | 未披露 | 定期报告 | 2025-10-31 |
| 2025-11-28 | 3103.40 | 未披露 | 定期报告 | 2025-10-21 |
| 2025-11-12 | 2716.84 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Exercise of common stock options
RSU Vesting
|
2025-09-30 |
| 2025-08-13 | 2707.66 | 未披露 | 定期报告 | 2025-08-08 |
| 2025-03-20 | 2707.21 | 未披露 | 定期报告 | 2025-03-17 |
| 2025-03-20 | 2698.66 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock for MedRx Agreement
Exercise of warrant
Initial public offering of common stock, net of offering costs of $4,618
Exercise of common stock options
Issuance of common stock for conversion of preferred stock
|
2024-12-31 |
| 2024-11-12 | 2697.02 | 未披露 | 定期报告 | 2024-11-08 |
| 2024-11-12 | 2696.82 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Exercise of common stock options
|
2024-09-30 |
| 2024-08-13 | 2695.90 | 未披露 | 定期报告 | 2024-08-08 |
| 2024-08-13 | 2695.06 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Exercise of common stock options
Issuance of common stock for MedRx Agreement
|
2024-06-30 |
| 2024-05-14 | 2688.40 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock for conversion of preferred stock
Initial public offering of common stock, net of offering cost of $4,643
Exercise of common stock options
Exercise of warrant
|
2024-03-31 |
| 2024-03-21 | 2688.40 | 未披露 | 定期报告 | 2024-03-01 |
| 2024-02-05 | 2557.44 | 未披露 |
更多>>
1.Common stock offered 8,040,000 Shares.
2.The number of shares of common stock to be outstanding after this offering is based on 17,534,360 shares of common stock outstanding as of September 30, 2023.
|
2024-02-02 |
Common stock offered 3,776,436 shares by the company
From March 31,2026 to June 30,2026
Exercise of common stock options
From December 31,2025 to March 31,2026
Exercise of common stock options
Issuance of common stock for conversion of the K2 term loan, net of issuance
Restricted stock units vesting
Issuance of common stock and pre-funded warrants in 2026 private placement, net of issuance costs
From December 31, 2024 to December 31, 2025
Exercise of common stock options
Issuance of common stock and pre-funded warrants in private placement, net of issuance costs
Issuance of common stock for conversion of the K2 term loan, net of issuance costs
Restricted stock units vesting
From June 30, 2025 to September 30, 2025
Exercise of common stock options
RSU Vesting
From December 31, 2023 to December 31, 2024
Issuance of common stock for MedRx Agreement
Exercise of warrant
Initial public offering of common stock, net of offering costs of $4,618
Exercise of common stock options
Issuance of common stock for conversion of preferred stock
From June 30, 2024 to September 30, 2024
Exercise of common stock options
From March 31, 2024 to June 30, 2024
Exercise of common stock options
Issuance of common stock for MedRx Agreement
From December 31, 2023 to March 31, 2024
Issuance of common stock for conversion of preferred stock
Initial public offering of common stock, net of offering cost of $4,643
Exercise of common stock options
Exercise of warrant
1.Common stock offered 8,040,000 Shares.
2.The number of shares of common stock to be outstanding after this offering is based on 17,534,360 shares of common stock outstanding as of September 30, 2023.